切换至 "中华医学电子期刊资源库"

中华卫生应急电子杂志 ›› 2018, Vol. 04 ›› Issue (05) : 273 -280. doi: 10.3877/cma.j.issn.2095-9133.2018.05.003

所属专题: 文献

论著

中西医结合创新治疗运动神经元病286例报告
岳茂兴1,(), 周培根2, 郝冬琳2, 李瑛2, 尹进南2, 郑琦函2, 杨学峰2, 徐冰心3, 吴静2, 吴娟2, 郁婷婷2, 钱亿超2, 朱晓瓞2, 冯斌2, 徐君晨2   
  1. 1. 213017 江苏常州,江苏大学附属武进医院;100101 北京,中国人民解放军第三○六医院
    2. 213017 江苏常州,江苏大学附属武进医院
    3. 100101 北京,中国人民解放军第三○六医院
  • 收稿日期:2018-09-05 出版日期:2018-10-18
  • 通信作者: 岳茂兴
  • 基金资助:
    国家重点实验室开放课题(SKLKF201601); 常州市2016年度基础应用研究项目(CJ20160006); 武进2016年度社会发展项目(WS201608)

Innovative therapy of combined Chinese and Western medicine in the treatment of motor neuron disease: report of 286 cases

Maoxing Yue1,(), Peigen Zhou2, Donglin Hao2, Ying Li2, Jinnan Yin2, Qihan Zheng2, Xuefeng Yang2, Bingxin Xu3, Jing Wu2, Juan Wu2, Tingting Yu2, Yichao Qian2, Xiaodie Zhu2, Bin Feng2, Junchen Xu2   

  1. 1. Affiliated Wujin Hospital of Jiangsu University, Changzhou 213017, China; 306 Hospital of PLA, Beijing 100101, China
    2. Affiliated Wujin Hospital of Jiangsu University, Changzhou 213017, China
    3. 306 Hospital of PLA, Beijing 100101, China
  • Received:2018-09-05 Published:2018-10-18
  • Corresponding author: Maoxing Yue
  • About author:
    Corresponding author: Yue Maoxing, Email:
引用本文:

岳茂兴, 周培根, 郝冬琳, 李瑛, 尹进南, 郑琦函, 杨学峰, 徐冰心, 吴静, 吴娟, 郁婷婷, 钱亿超, 朱晓瓞, 冯斌, 徐君晨. 中西医结合创新治疗运动神经元病286例报告[J]. 中华卫生应急电子杂志, 2018, 04(05): 273-280.

Maoxing Yue, Peigen Zhou, Donglin Hao, Ying Li, Jinnan Yin, Qihan Zheng, Xuefeng Yang, Bingxin Xu, Jing Wu, Juan Wu, Tingting Yu, Yichao Qian, Xiaodie Zhu, Bin Feng, Junchen Xu. Innovative therapy of combined Chinese and Western medicine in the treatment of motor neuron disease: report of 286 cases[J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2018, 04(05): 273-280.

目的

观察中西医结合创新疗法治疗运动神经元病(MND)患者的疗效。

方法

运动神经元病属中医"痿证"范畴。本研究在常规综合治疗基础上,采用一种用于促进神经损伤修复的药物组合物[精氨酸1.5~5 g,异亮氨酸1.5~5 g,亮氨酸2.5~7.5 g,赖氨酸1.5~5 g,蛋氨酸0.25~1.5 g,苯丙氨酸0.25~1.5 g,苏氨酸1.5~5 g,色氨酸0.25~1.5 g,缬氨酸2.5~7.5 g,组氨酸1.5~4 g,甘氨酸1.5~4 g,丙氨酸1.5~5 g,脯氨酸1.5~4 g,天冬酰胺0.05~1.5 g,半胱氨酸0.05~1.5 g,谷氨酸1.5~5 g,丝氨酸0.25~2.5 g,酪氨酸0.05~1.5 g,L~鸟氨酸0.25~4 g,天冬氨酸0.5~2.5 g;维生素(维生素B1 1~2 mg,维生素B2 1~2 mg,维生素B6 3~10 g,维生素C 1~3 g)]及中药"滋痿膏"。对2015年4月至2018年3月江苏大学附属武进医院收治的286例MND患者进行治疗,其中男性199例,女性87例;年龄26~81岁,平均年龄(53.7±10.7)岁。用法:将上述药物组合物配制在1个三升输液袋内进行静脉输注,1次/d,28 d为1个疗程,停药2周后行下一疗程,连续治疗≥1个疗程并持续随访至首次用药后第6个月。同时,在治疗期间每天于饭后2 h口服中药"滋痿膏",2次/d。观察治疗前后患者的肌萎缩侧索硬化症改良功能评分量表(ALSFRS-R评分)、疾病进展率及临床表现等变化情况。

结果

286例患者中死亡16例(5.6%),死亡原因均为疾病晚期呼吸衰竭。国际ALSFRS-R评分上升占20.3%(58/286),评分维持不变占15.0%(43/286)。仍有64.7%(185/286)的患者在经过治疗后评分持续下降,但评分下降的速度较治疗前有所减缓。治疗后,MND患者疾病进展率[0.583(0.478)分/月]低于治疗前[0.600(0.533)分/月],差异有统计学意义(Z=-2.088,P<0.05),且174例(60.8%)患者的疾病进展率在治疗后较前下降。临床症状改善情况:肌肉萎缩好转、肌力增加12例(4.2%),舌肌萎缩、言语不清好转6例(2.1%),流涎好转9例(3.1%),吞咽功能改善15例(5.2%),四肢活动度增加11例(3.8%),3例(1.0%)不能站立或行走的患者恢复部分行走能力,呼吸困难好转6例(2.1%)。

结论

本疗法一方面通过滋痿膏起到补益脾肾、扶元起痿、益气温阳、补肾壮骨、疏肝理气、养荣生肌、扶正祛邪、强骨滋痿、双向免疫调节的作用;另一方面,通过疗法中所提供的各种氨基酸与维生素B6等,能够为患者提供充足的代谢底物及强劲的动能,促进机体酶代谢、利尿与解毒,达到保护大脑及神经系统功能、改善肝功能、提高机体免疫功能的功效。两者相辅相成,使损伤的神经细胞在一定程度上得到修复。该中西医结合创新疗法疗效确切,且无毒、无害、无副作用、重复性好。

Objective

To observe therapeutic efficacy of integrated traditional Chinese and Western medicine for motor neuron disease (MND).

Methods

Motor neuron disease belongs to an impotence syndrome according to traditional Chinese medicine. In this study, a pharmaceutical composition for promoting nerve damage repair and nourishing flaccidity extract included the following main components: arginine (1.5-5 g), isoleucine (1.5-5 g), lysine (2.5-7.5 g), methionine (0.5-1.5 g), phenylalanine (0.5-5 g), tryptophan (0.5-1.5 g), valine (2.5-7.5 g), histidine (1.5-4 g), glycine (1.5-4 g), alanine (1.5-5 g), proline (1.5-4 g), asparagine (0.05-1.5 g), cysteine (0.05-1.5 g), cysteine (1.5-5 g), serine (0.25-2.5 g), tyrosine (0.05-1.5 g), L-ornithine (0.25-4 g), aspartic acid (0.5-2.5 g) and vitamins (vitamin B1 1-2 mg, vitamin B2 1-2 mg, vitamin B6 3-10 g and vitamin C 1-3 g)on the basis of conventional comprehensive treatment. 286 MND patients were treated in Wujin Hospital from April 2015 to March 2018. 199 cases were males and 87 cases were females, aged from 26 to 81 years, with the average age (53.7±10.7 years). The above composition was prepared in a three-liter infusion bag for intravenous infusion, once a day for 28 days for a course of treatment. The next course should be followed after drug withdrawal for 2 weeks and the treatment lasted at least for 1 course, followed by a continuous follow-up until the 6th month after the first dose. At the same time, nourishing flaccidity extract of traditional Chinese medicine was orally administrated 2 h after meals twice a day. The neurological functional evaluation was done with amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R), disease progression rate and clinical manifestations in all patients pre- and post-treatment.

Results

After treatment, 16 patients (5.6%) died from advanced respiratory failure in the terminal phase of disease. Patients with increased scores accounted for 20.3%(58/286)and those with remained unchanged for 15.0% (43/286) according to International ALSFRS-R scores. There were still 64.7% (185/286) of patients whose scores continued to decline after treatment, but the rate of decline was slower than those before treatment. The disease progression rate after treatment [0.583 (0.478) point/month] was lower than that before treatment [0.600 (0.533) point/month], the difference was statistically significant (Z=-2.088, P<0.05), and the disease progression rate of 174 patients (60.8%) decreased after treatment. Symptoms of muscular atrophy and muscle strength were improved in 12 cases (4.2%); that of atrophy of tongue muscle and speech inarticulate were improved in 6 cases (2.1%); that of salivation were improved in 9 cases (3.1%); swallowing function was improved in 15 cases (5.2%); 11 patient (3.8%)increased limb mobility; 3 patients (1.0%) who could not stand or walk restored partial walking ability; Six cases (2.1%) showed improvement in dyspnea.

Conclusions

On the one hand, the therapy plays a role of reinforcing spleen and kidney functions, Fuyuan Qiwei, Yiqi Wenyang, Bushen Zhuanggu, Shugan Liqi, Yangrong Shengji , Fuzheng Quxie, and Qianggu Ziwei, with dual immunomodulatory effects. On the other hand, a variety of amino acid and vitamin B6 can provide patients with adequate metabolic substrate and strong energy and promote the body's enzyme metabolism, diuresis and detoxification. With this therapy, the damaged nerve cells are repaired to some extent, the nervous system functions are protected, and the liver and immune functions are improved. The combination of traditional Chinese medicine and Western medicine is effective, non-toxic and harmless, with no side effects and good repeatability.

表1 MND诊断标准(Awaji标准)[10]
图1 286例MND患者采用中西医结合创新疗法治疗前后的ALSFRS-R评分变化
1
岳茂兴,邹德威,闵庆旺,等.中国首飞航天员主着陆场的医疗救护保障[J]. 中华航空航天医学杂志,2003,14(4):193-195.
2
岳茂兴,邹德威,闵庆旺,等.从载人航天航天员主着陆场的医疗救护谈现场急救新理论的可行性[J].中华急诊医学杂志,2004,13(1):7-9.
3
岳茂兴,邹德威,张坚,等.神舟六号飞船航天员主着陆场医疗卫勤保障的经验体会[J]. 中华急诊医学杂志,2005,14(12):973-977.
4
岳茂兴,刘志国,周雪峰,等.神舟五、六号航天员医疗卫生应急保障的创新点及其救护对策研究[J/CD],中华卫生应急电子杂志,2015,1(2):92-95.
5
刘志国,邹德威,张坚,等. "神舟"七号主着陆场航天员的医疗保障与救护[J].中华急诊医学杂志,2011,20(11):14-16.
6
姜玉峰,岳茂兴.解毒固本冲剂治疗腹腔感染合并全身炎性反应综合征的临床研究[J].世界华人消化杂志,2003,7(9):1657-1659.
7
岳茂兴,姜玉峰,李瑛,等.柴黄参祛毒固本冲剂治疗严重化学性肺损伤89例临床研究[J].中国中西医结合急救学杂志,2013,20(3): 159-161.
8
姜玉峰,岳茂兴.解毒固本冲剂对大鼠肿瘤坏死因子α和白介素2及病理形态学改变的影响[J].中国中西医结合急救杂志,2000, 7(1):51-53.
9
岳茂兴,姜玉峰,周培根,等.柴黄参祛毒固本冲剂治疗腹部外科脓毒症的临床研究[J/CD].中华卫生应急电子杂志,2015,1(3):220-222.
10
蒋雨平.运动神经元病[J].中国临床神经科学,2014,22(6):663-665,671.
11
国家中医药管理局医政司. ZY/T001[1].1-94中医病证诊断疗效标准[S].北京:中国中医药出版社,2017.
12
Cedarbaum JM,Stambler N,Malta E,et al.The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)[J].J Neurol Sc,1999,169(1-2):13-21.
13
Lee M,McCambridge A.Clinimetrics: Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R)[J].J Physiother,2018,64(4):269-270.
14
Chiò A,Mora G,Leone M,et al.Early symptom progression rate is related to ALS outcome: a prospective population based study[J].Neurology,2002,59(1):99-103.
15
Gomeni R,Fava M.Amyotrophic lateral sclerosis disease progression model[J]. Amyotroph Lateral Scler Frontotemporal Degener,2014,15(1-2):119-129.
16
Gordon PH,Cheung YK.Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS[J].Neurology,2006,66(7):1314-1315.
17
Proudfoot M,Jones A,Talbot K,et al.The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset[J].Amyotroph Lateral Scler Frontotemporal Degener,2016,17(5-6):414-425.
18
康丽,胡芳芳,靳娇婷,等.肌萎缩侧索硬化症患者生存期的影响因素分析[J].西安交通大学学报(医学版),2018,39(5):639-643.
19
郑勇,臧大维.肌萎缩性侧索硬化患者粒细胞集落刺激因子的水平[J].广东医学,2017,38(18):2806-2809.
20
吴咸中,李恩,陈士奎.中国中西医结合开拓者[M].北京:中国中医药出版社,2018:347.
21
张印生,韩学杰.孙思邈医学全书[M].北京:中国中医药出版社,2009:1.
22
黄诒森.生物化学[M].第3版.北京:人民卫生出版社,1994: 125.
23
谢海,王世文,曹宏霞,等.大剂量γ-氨基丁酸与二巯基丙磺酸钠联合维生素B6对毒鼠强中毒大鼠的解毒作用[J].中华急诊医学杂志,2010,19(7): 703-707.
24
Martin DL,Rimvall K.Regulation of gamma-aminobutyric acid synthesis in the brain[J].J Neurochem,1993,60(2):395-407.
25
GJB 7141-2011,液体推进剂损伤诊断标准及处理原则[S].北京:中国人民解放军总后勤部,2011:5.
26
中国人民解放军总后勤部卫生部.战伤救治规则[S].北京:中国人民解放军总后勤部卫生部,2006:94-95.
[1] 张华, 孙宇, 乡世健, 李樱媚, 王小群. 循环肿瘤细胞预测晚期胃肠癌患者化疗药物敏感性的研究[J]. 中华普通外科学文献(电子版), 2023, 17(06): 422-425.
[2] 莫波, 王佩, 王恒, 何志军, 梁俊, 郝志楠. 腹腔镜胃癌根治术与改良胃癌根治术治疗早期胃癌的疗效[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 644-647.
[3] 索郎多杰, 高红桥, 巴桑顿珠, 仁桑. 腹腔镜下不同术式治疗肝囊型包虫病的临床疗效分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 670-673.
[4] 唐浩, 梁平, 徐小江, 曾凯, 文拨辉. 三维重建指导下腹腔镜右半肝加尾状叶切除治疗Bismuth Ⅲa型肝门部胆管癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 688-692.
[5] 汪毅, 许思哲, 任章霞. 胸乳入路腔镜单侧甲状腺叶切除术与开放手术对分化型甲状腺癌患者术后恢复的影响[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 542-545.
[6] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[7] 邰清亮, 施波, 侍新宇, 陈国梁, 陈俊杰, 武冠廷, 王索, 孙金兵, 顾闻, 叶建新, 何宋兵. 腹腔镜次全结肠切除术治疗顽固性慢传输型便秘的疗效分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 478-483.
[8] 徐红莉, 杨钰琳, 薛清, 张茜, 马丽虹, 邱振刚. 体外冲击波治疗非特异性腰痛疗效的系统评价和Meta分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(05): 307-314.
[9] 姜里蛟, 张峰, 周玉萍. 多学科诊疗模式救治老年急性非静脉曲张性上消化道大出血患者的临床观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 520-524.
[10] 梁文龙, 曹杰, 黄庆, 林泳, 黄红丽, 杨平, 李冠炜, 胡鹤. 信迪利单抗联合瑞戈非尼治疗晚期结直肠癌的疗效与安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 409-413.
[11] 高显奎, 赵太云, 陆兴俊, 张洪领, 房修罗, 闫碧春, 王胤, 王永翠, 刘苗苗, 冉若男. 内镜电凝止血与组织胶注射治疗上消化道溃疡伴出血的疗效观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 452-455.
[12] 张景旭, 李德舫, 由上可, 张玉田. 贝伐珠单抗与安罗替尼联合奥沙利铂治疗晚期直肠癌的临床疗效[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 289-293.
[13] 杨镠, 秦岚群, 耿茜, 李栋庆, 戚春建, 蒋华. 可溶性免疫检查点对胃癌患者免疫治疗疗效和预后的预测价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 305-311.
[14] 盛静, 梅勇, 夏佩, 王晓林. 乌苯美司联合伊立替康二线治疗晚期胃癌的临床研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 317-321.
[15] 李莹倩, 李华山. 基于真实世界的完全性直肠脱垂治疗方式评价[J]. 中华临床医师杂志(电子版), 2023, 17(06): 700-705.
阅读次数
全文


摘要